Lorvotuzumab mertansine
- Generic Name
- Lorvotuzumab mertansine
- Drug Type
- Biotech
- CAS Number
- 1008106-64-6
- Unique Ingredient Identifier
- 0IVD6ASY0W
- Background
Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT01237678
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇪🇸Hospital Universitario Virgen del Rocio, Sevilla, Spain
🇬🇧Royal Marsden, London, London, United Kingdom
IMGN901 in Combination With Lenalidomide and Dexamethasone
- Conditions
- Multiple Myeloma
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00991562
- Locations
- 🇺🇸
Comprehensive Cancer Center of the Desert, Palm Springs, California, United States
🇺🇸Weill Medical College, New York, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
- Conditions
- Ovarian CancerMerkel Cell CarcinomaSCLC
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT00346385
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Oklahoma University, Oklahoma City, Oklahoma, United States
🇺🇸M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00346255
- Locations
- 🇦🇷
Juan Domingo Peron 1500 - (B1629AHJ) Pilar, Buenos Aires, Argentina
🇺🇸St. Vincent's Comprehensive Cancer Center - Manhattan, New York, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer
- First Posted Date
- 2003-07-24
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT00065429
- Locations
- 🇺🇸
Greater Dayton Cancer Center, Kettering, Ohio, United States
🇺🇸The Ohio State University, Colombus, Ohio, United States
🇺🇸Baystate Medical Center, Springfield, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.